This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Zeposia (ozanimod)
General Description:
Zeposia (ozanimod) is an oral medication used for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS) and ulcerative colitis (UC).
Ozanimod is a selective sphingosine-1-phosphate (S1P) receptor modulator that helps prevent immune cells (lymphocytes) from leaving lymph nodes and reaching the central nervous system or intestinal tissues. This action reduces inflammation, helping to slow disease progression in MS and induce and maintain remission in UC.
Disease Indications:
• Multiple Sclerosis (MS)
• Ulcerative Colitis (UC)
Manufacturer:
Bristol-Myers Squibb
Usage:
Oral
Medicine Approved by:
• European Medicines Agency (EMA)
• Food and Drug Administration (FDA)
• Health Canada
• Therapeutic Goods Administration (TGA)
Package:
• 7-day starter pack (4 capsules × 0.23 mg + 3 capsules × 0.46 mg)
• Bottle with 28 capsules × 0.92 mg
Shipping:
Room Temperature Shipping
Zeposia is stable at room temperature and does not require refrigeration. It is shipped under standard shipping conditions (15°C to 25°C) to maintain product stability and potency throughout transit.
This standard shipping method is efficient and cost-effective, ensuring that Zeposia arrives safe, stable, and ready for patient use.
How to Access Zeposia (ozanimod) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Zeposia (ozanimod) is not yet approved or commercially available in India, MitoGENE can assist patients and healthcare providers in legally obtaining it through the Named Patient Program (NPP).
Here’s how the process works:
